このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

PET/CT Imaging in Carriers of TTR Mutations (EPIC-TTR)

2026年5月15日 更新者：Justin Grodin、University of Texas Southwestern Medical Center

Iodine-124 Evuzamitide PET/CT Imaging in Carriers of TTR Mutations

The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using a new radiotracer dye (iodine-124 evuzamitide, I-124E).

Participants will undergo a screening that includes a medical history review and completion of quality-of-life surveys. Once screening is complete, participants will undergo an imaging test called a positron emission tomography (PET) scan combined with computed tomography (PET/CT) to make images of the body. The new radiotracer dye (I-124E, a radioactive contrast) will be used during the PET/CT to make amyloidosis visible in the heart and body.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

This will be a cross-sectional cohort study of 50 carriers of pathogenic TTR alleles without HF; 10-race matched non-carrier controls; and 20 patients with ATTR-CA. Participants will undergo standardized, PET/CT direct amyloid imaging assessments with I-124E to test the hypothesis that carriers of pathogenic TTR alleles without HF will have LV%ID intermediate to non-carrier controls and patients with ATTR-CA. This will address the fundamental questions of whether and to what extent cardiac amyloid infiltration is present in carriers of pathogenic TTR alleles prior to ATTR-CA disease onset.

研究の種類

観察的

入学 (推定)

80

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

  • アメリカ
    • Texas
      • Dallas、Texas、アメリカ、75248
        • UT Southwestern Medical Center
        • 主任研究者：
          • Justin L Grodin, MD MPH
        • 副調査官：
          • Lori Roth, PA-C
        • コンタクト：
        • 副調査官：
          • Vlad Zaha, MD PhD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

サンプリング方法

非確率サンプル

調査対象母集団

We will enroll 50 carriers of pathogenic TTR alleles without HF, 20 patients with ATTR-CA, and 10-race matched non-carrier controls to have PET/CT I-124E imaging.

説明

A. Pathogenic TTR Allele Carriers without HF

Inclusion:

  • men and women ages 30-80 who are pathogenic allele TTR carriers without history of HF (this will be assessed by study personnel and defined as : 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)
  • have already completed the protocol for NCT05489549 at UT Southwestern only

Exclusion:

  • a self-reported history or clinical history of HF
  • other known causes of cardiomyopathy
  • history of light-chain cardiac amyloidosis
  • prior type 1 myocardial infarction
  • cardiac transplantation
  • liver transplantation
  • body weight or habitus that exceeds the site-specific PET/CT parameters
  • estimated glomerular filtration rate ≤30 mL/min/1.73 m2
  • inability to safely undergo PET/CT
  • participating in a clinical trial for ATTR treatments or taking a fibril deleting agent
  • pregnancy or breastfeeding
  • patients taking heparin or heparin derivatives for anticoagulation
  • allergy to potassium iodide
  • known uncorrected thyroid disorder

B. Subjects with symptomatic hATTR-CA (may be supplemented with other ATTR-CA genotypes including wild-type in the occasion of slow enrollment):

Inclusion:

  • men and women ages 30-80 who have symptomatic V122I hATTR-CA as determined by a history of HF (this will be assessed by study personnel and defined as : 1) history of hospitalization within the previous 12 months for management of HF; 2) an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) a clinical diagnosis of HF from a treating clinician)
  • hATTR-CA previously diagnosed histologically by amyloid staining and tissue typing with immunohistochemistry or mass spectrometry or by bone scintigraphy in without abnormal M-protein
  • TTR gene sequencing confirming the TTR variant
  • have already completed the protocol for NCT05489549 at UT Southwestern only

Exclusion:

  • other known causes of cardiomyopathy
  • history of light-chain cardiac amyloidosis
  • cardiac transplantation
  • liver transplantation
  • history of type I myocardial infarction
  • body weight or habitus that exceeds the site-specific PET/CT parameters
  • estimated glomerular filtration rate ≤30 mL/min/1.73 m2
  • inability to safely undergo PET/CT
  • participating in a clinical trial for ATTR treatments or taking a fibril deleting agent
  • patients taking heparin or heparin derivatives for anticoagulation
  • pregnancy or breastfeeding
  • allergy to potassium iodide
  • known uncorrected thyroid disorder

C. Non-carrier race-matched controls:

Inclusion:

  • men and women ages 30-80 who are non-carriers without history of HF (this will be assessed by study personnel and defined as: 1) No history of hospitalization within the previous 12 months for management of HF; 2) Without an elevated B-type natriuretic peptide level ≥100 pg/mL or NT-proBNP ≥360 pg/mL within the previous 12 months; or 3) No clinical diagnosis of HF from a treating clinician
  • have previously enrolled in the Dallas Heart Study

Exclusion:

  • a self-reported history or clinical history of HF
  • other known causes of cardiomyopathy
  • history of light-chain cardiac amyloidosis
  • prior type 1 myocardial infarction
  • cardiac transplantation
  • liver transplantation
  • body weight or habitus that exceeds the site-specific PET/CT parameters
  • estimated glomerular filtration rate ≤30 mL/min/1.73 m2
  • inability to safely undergo PET/CT
  • participating in a clinical trial for ATTR treatments or taking a fibril deleting agent
  • patients taking heparin or heparin derivatives for anticoagulation
  • pregnancy or breastfeeding
  • allergy to potassium iodide
  • known uncorrected thyroid disorder

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Pathogenic TTR Allele Carriers without Heart Failure
診断テスト：Iodine-124 Evuzamitide (I-124E)
I-124E is a novel amyloidophilic peptide radiotracer that binds via electrostatic interactions to electronegative glycosaminoglycans and amyloid protein fibrils - both are ubiquitous among amyloid deposits. PET/CT I-124E has acceptable dosimetry estimates and is acceptable for whole-body PET/CT imaging. Data from patients with amyloidosis has established that tracer uptake is present in locations of clinically anticipated amyloid deposits and in locations not clinically appreciated, but also consistent with the distribution of amyloid in the human body (e.g. heart, kidney, spleen).
Subjects with Symptomatic ATTR-CA
診断テスト：Iodine-124 Evuzamitide (I-124E)
I-124E is a novel amyloidophilic peptide radiotracer that binds via electrostatic interactions to electronegative glycosaminoglycans and amyloid protein fibrils - both are ubiquitous among amyloid deposits. PET/CT I-124E has acceptable dosimetry estimates and is acceptable for whole-body PET/CT imaging. Data from patients with amyloidosis has established that tracer uptake is present in locations of clinically anticipated amyloid deposits and in locations not clinically appreciated, but also consistent with the distribution of amyloid in the human body (e.g. heart, kidney, spleen).
Non-carrier race-matched controls
診断テスト：Iodine-124 Evuzamitide (I-124E)
I-124E is a novel amyloidophilic peptide radiotracer that binds via electrostatic interactions to electronegative glycosaminoglycans and amyloid protein fibrils - both are ubiquitous among amyloid deposits. PET/CT I-124E has acceptable dosimetry estimates and is acceptable for whole-body PET/CT imaging. Data from patients with amyloidosis has established that tracer uptake is present in locations of clinically anticipated amyloid deposits and in locations not clinically appreciated, but also consistent with the distribution of amyloid in the human body (e.g. heart, kidney, spleen).

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
LV % Injected dose
時間枠：PET/CT Scan Visit
Evidence of subclinical cardiac amyloid infiltration as measured by PET/CT quantification imaging with I-124E. This will be defined as LV % injected dose (LV%ID = volume of interest [VOI] mean activity concentration in the LV X VOI volume / injected activity). LV%ID is an ideal metric to assess cardiac amyloid burden because it is: 1) correlated with validated metrics assessing cardiac amyloid burden; 2) sensitive for detection of early disease (patchy vs. diffuse uptake); and 3) highly repeatable and standardizable to other metrics of radiotracer uptake. LV%ID is adjusted for injected activity, but not for body weight, because the latter is unnecessary for a radiotracer accumulating in the heart and specific organs, not in the whole body.
PET/CT Scan Visit

二次結果の測定

結果測定
時間枠
LVFW SUVR, mean
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
LVFW wall SUVR, max
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
IVS SUVR, mean
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
IVS SUVR, max
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
RVFW SUVR, mean
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
RVFW SUVR, max
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
RV % Injected Dose (RV%ID)
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
LV Cardiac Amyloid Activity (CAA)
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
LV Target-to-Background Ratio (TBR)
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
RV Cardiac Amyloid Activity (CAA)
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
RV Target-to-Background Ratio (TBR)
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
Left Atrial Uptake
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
Right Atrial Uptake
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
Liver Uptake
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
Spleen Uptake
時間枠：PET/CT Scan Visit
PET/CT Scan Visit
Kidney Uptake
時間枠：PET/CT Scan Visit
PET/CT Scan Visit

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

University of Texas Southwestern Medical Center

協力者

National Heart, Lung, and Blood Institute (NHLBI)
Bayer

捜査官

  • 主任研究者：Justin L Grodin, MD MPH、University of Texas Southwestern Medical Center

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年8月1日

一次修了 (推定)

2030年6月30日

研究の完了 (推定)

2030年6月30日

試験登録日

最初に提出

2026年5月8日

QC基準を満たした最初の提出物

2026年5月8日

最初の投稿 (実際)

2026年5月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月19日

QC基準を満たした最後の更新が送信されました

2026年5月15日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • STU-2026-0286
  • R01HL172993 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する